Paired box gene 8 (PAX8) is a transcription factor expressed in tissues of Müllerian origin (fallopian tube, endometrium, endocervix and ovarian surface epithelium), as well as in thyroid and renal epithelium.

Immunohistochemical detection of PAX8 has become a cornerstone in diagnostic surgical pathology for confirming Müllerian lineage, resolving challenging differential diagnoses in gynecologic tumor classification, and distinguishing primary gynecologic malignancies from metastatic disease. CE/IVD Anti-PAX8 reagents optimized for automated IHC platforms provide reliable nuclear staining on FFPE specimens.

Clinical utility in gynecologic pathology

• Lineage identification: PAX8 is highly sensitive and specific for Müllerian-derived epithelial cells and is routinely used to confirm ovarian, tubal, endometrial and endocervical origin in neoplastic and non-neoplastic tissues.
• Ovarian tumor evaluation: Strong nuclear PAX8 staining supports primary ovarian epithelial neoplasia (serous, endometrioid, clear cell) and helps differentiate these tumors from metastatic gastrointestinal or breast cancers.
• Primary versus metastatic carcinoma: When used in a diagnostic panel (for example WT1, ER, CK7/CK20, calretinin), PAX8 improves diagnostic accuracy in effusion cytology, small biopsies and metastatic deposits.

Clinical utility in breast pathology

• Low expression in primary breast carcinoma: Most primary breast carcinomas are PAX8-negative. A minority of high-grade or triple-negative breast cancers may show focal positivity, which requires cautious interpretation in the context of morphology and additional markers.
• Evaluation of metastasis: PAX8 positivity in a breast lesion suggests metastatic Müllerian, renal or thyroid carcinoma rather than primary breast carcinoma. Therefore, PAX8 is particularly valuable when assessing unusual breast tumors or metastatic workups.

Key features of Anti-PAX8 CE/IVD antibodies

• High nuclear specificity: Validated clones provide crisp, clean nuclear staining with minimal background, improving reproducibility and diagnostic confidence.
• Platform optimization: Anti-PAX8 solutions are commonly validated on automated IHC systems with defined antigen-retrieval and detection conditions.
• Comprehensive validation data: High-quality reagents include sensitivity and specificity data across tissue panels (Müllerian tissues, renal and thyroid controls), as well as reproducibility studies and inter-laboratory comparisons.
• Recombinant monoclonal options: Recombinant clones minimize batch-to-batch variation and improve long-term stability, ensuring consistent performance over time.

Advantages of CE/IVD Anti-PAX8 for diagnostic laboratories

• Regulatory compliance and ease of implementation: CE/IVD reagents simplify integration into routine diagnostic workflows.
• Strong diagnostic value: PAX8 enhances diagnostic accuracy in Müllerian lesions and metastatic tumor evaluation when used as part of an integrated panel.